ADMA Biologics to Present at the J.P. Morgan Healthcare Conference on January 12, 2026

Rhea-AI Summary

ADMA Biologics (Nasdaq: ADMA) announced that Adam Grossman, President and CEO, will deliver a podium presentation at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PT.

A live audio webcast will be available under Events & Webcasts in the company investor website and an archived webcast will be posted after the event.

Key Figures

Conference date January 12, 2026 J.P. Morgan Healthcare Conference presentation

Presentation time 9:45 a.m. PT J.P. Morgan Healthcare Conference session

Market Reality Check

$18.07 Last Close

Volume Volume 1,957,423 vs 20-day average 2,216,006 (0.88x typical activity ahead of this conference update). normal

Technical Shares at $17.88 are trading below the 200-day moving average of $18.19 before the conference news.

Peers on Argus

ADMA was down 1.97% with mixed peer moves: ACAD (-1.72%), MIRM (-1.31%), ZLAB (-0.57%), MTSR (-0.34%), PTGX (+0.74%). This points to stock-specific dynamics rather than a broad sector move ahead of the J.P. Morgan presentation.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 05	Q3 2025 earnings	Positive	+5.1%	Strong Q3 revenue, net income and raised multi-year guidance with margin drivers.
Oct 29	Earnings call schedule	Neutral	-0.3%	Announcement of Q3 2025 results date and accompanying conference call details.
Aug 06	Q2 2025 earnings	Positive	-9.7%	Strong Q2 growth, yield enhancement start, refinancing and long-term revenue outlook.
Jul 30	Earnings call schedule	Neutral	+1.8%	Scheduling second quarter 2025 results release and webcast for investors.

Pattern Detected

Earnings reports have produced mixed reactions, including one notable selloff on strong results, while scheduling-related conference releases have historically had modest price impact.

Recent Company History

Over the last few quarters, ADMA reported strong growth, with Q2 and Q3 2025 revenues of $122.0M and $134.2M and positive net income and Adjusted EBITDA. These earnings updates were accompanied by yield-enhancement initiatives, a $300M debt refinancing, new Boca Raton facilities, and raised revenue and EBITDA guidance through 2026. Price reactions ranged from a -9.65% drop to a +5.06% gain, while simple scheduling announcements for earnings calls and webcasts showed relatively small moves. Today’s J.P. Morgan conference appearance fits the pattern of communication-focused news rather than a new financial or clinical milestone.

Market Pulse Summary

This announcement highlights ADMA’s upcoming podium presentation at the J.P. Morgan Healthcare Conference on January 12, 2026 at 9:45 a.m. PT, offering management a platform to communicate its strategy and recent performance. Recent history includes strong Q2 and Q3 2025 revenues and raised guidance, along with active capital-structure management. Investors may focus on webcast commentary for any updates to growth, manufacturing initiatives, or capital deployment, while considering that prior communication-only releases have generally produced modest stock reactions.

AI-generated analysis. Not financial advice.

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a podium presentation at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 9:45 a.m. PT.

A live audio webcast of the call will be available under “Events & Webcasts” in the investor section of the Company’s website, https://ir.admabiologics.com/events-webcasts. An archived webcast will be available on the Company’s website after the event.

About ADMA Biologics, Inc. (ADMA)

ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV™ (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM^® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB^® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumonia. ADMA manufactures its immune globulin products at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides its blood plasma for the manufacture of its products. ADMA’s mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons. ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit www.admabiologics.com.

INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ADMA@argotpartners.com

FAQ

When will ADMA (ADMA) present at the J.P. Morgan Healthcare Conference in 2026?

ADMA will present on Monday, January 12, 2026 at 9:45 a.m. PT.

Who is presenting for ADMA (ADMA) at the January 12, 2026 J.P. Morgan Healthcare Conference?

Adam Grossman, President and Chief Executive Officer, will deliver the podium presentation.

How can investors access ADMA's January 12, 2026 J.P. Morgan presentation?

A live audio webcast will be available via the Events & Webcasts page on the company's investor website.

Will ADMA (ADMA) provide a replay of the January 12, 2026 presentation?

Yes. An archived webcast will be posted on the company's investor website after the event.

Where is the ADMA webcast for the January 12, 2026 presentation hosted?

The webcast is hosted on ADMA's investor site under https://ir.admabiologics.com/events-webcasts.